1. E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803 Untreated Stage III/IV, or Locally Extensive (>1/3 mediastinum) HL n=854 ABVD x 6-8 + IFRT (36 Gy) to bulky mediastinal lesions n=428 Stratification 0-2 vs 3-7 adverse factors* Locally extensive vs Stage III/IV Stanford V + IFRT (36 Gy) to lesions >5 cm n=426 R ABVDDosage Doxorrubicin25 mg/m 2 IV días 1 y 15 Bleomycin10 u/m 2 IV días 1 y 15 Vinblastine6 mg/m 2 IV días 1 y 15 Dacarbazine375 mg/m 2 IV días 1 y 15 Stanford VDosage Doxorrubicin25 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Vinblastine6 mg/m 2 IV weeks 1, 3, 5, 7, 9 and 11 Nitrogen mustard6 mg/m 2 IV weeks 1, 5, and 9 Etoposide60 mg/m 2 x2 V weeks 3, 7, and 11 Vincristine1.4 mg/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Bleomycin5 u/m 2 IV weeks 2, 4, 6, 8, 10 and 12 Prednisone40 mg q other day x 12 weeks (Taper week 10-12) Creada por: Mauricio Lema Medina MD 1/2 Outcomes Failure-Free Survival (FFS)** Overall Survival (OS) FFS: Time from randomization to progression, relapse or death, whichever occurred first

2. E2496 / NCI-C / SWOG / CALG-B: ABVD vs Stanford V in Locally Extensive and Advanced Stage Hodgkin Lymphoma (HL) Gordon LI, et al. ECOG 2496, J Clin Oncol DOI: 10.1200/JCO.2012.43.4803 Creada por: Mauricio Lema Medina MD 2/2 % ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.

3. Treatment of Advanced Hodgkin Lymphoma: The More Things Change, the More They Stay the Same Longo DL. J Clin Oncol DOI:10.1200/JCO.2012.44.7235